Cargando…
Novel targeted therapies for mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by short median survival despite intensive therapies. The clinical behavior of MCL most likely relates to the complex pathophysiology of the disease which includes its genetic hallmark, the chromosomal translocation t(11;14)...
Autores principales: | Alinari, Lapo, Christian, Beth, Baiocchi, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326650/ https://www.ncbi.nlm.nih.gov/pubmed/22361516 |
Ejemplares similares
-
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020) -
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
por: Chan, Wing Keung, et al.
Publicado: (2023) -
Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022) -
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022) -
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
por: Jang, Ja-Young, et al.
Publicado: (2022)